Gå till forskningen.

Publikationsdata från Europe PMC och PubMed. Följ källhänvisningar från ämnesregistret till originalpublikationerna.

Publikationer som ChEBI hänvisar till för ACT-132577. Visa hela publikationsregistret

En publikationsträff är inte en slutsats. Publikationslistan visar bibliografiska uppgifter. Eventuella forskningsutdrag visas separat med originalunderlag. En källhänvisning visar inte i sig effekt, dosering eller säkerhet.

Publikationer i urvalet

8 träffar

Bibliografisk träff 2014-03-01

Pharmacokinetics of the novel dual endothelin receptor antagonist macitentan in subjects with hepatic or renal impairment.

Sidharta PN, Lindegger N, Ulč I, Dingemanse J.

J Clin Pharmacol · research support, non-u.s. gov't; clinical trial, phase i; journal article · DOI 10.1002/jcph.193

Bibliografisk träff 2013-09-04

Safety, tolerability, pharmacokinetics, and pharmacodynamics of macitentan, an endothelin receptor antagonist, in an ascending multiple-dose study in healthy subjects.

Sidharta PN, van Giersbergen PL, Dingemanse J.

J Clin Pharmacol · research support, non-u.s. gov't; randomized controlled trial; journal article · DOI 10.1002/jcph.152

Bibliografisk träff 2013-08-01

Investigation of the effects of ketoconazole on the pharmacokinetics of macitentan, a novel dual endothelin receptor antagonist, in healthy subjects.

Atsmon J, Dingemanse J, Shaikevich D, Volokhov I, Sidharta PN.

Clin Pharmacokinet · research support, non-u.s. gov't; randomized controlled trial; journal article · DOI 10.1007/s40262-013-0063-8

Bibliografisk träff 2013-06-26

Pharmacokinetics of macitentan in caucasian and Japanese subjects: the influence of ethnicity and sex.

Bruderer S, Marjason J, Sidharta PN, Dingemanse J.

Pharmacology · research support, non-u.s. gov't; clinical trial, phase i; journal article · DOI 10.1159/000351704

Bibliografisk träff 2011-12-22

Effect of cyclosporine and rifampin on the pharmacokinetics of macitentan, a tissue-targeting dual endothelin receptor antagonist.

Bruderer S, Aänismaa P, Homery MC, Häusler S, Landskroner K, Sidharta PN, Treiber A, Dingemanse J.

AAPS J · research support, non-u.s. gov't; research-article; clinical trial, phase i; journal article · DOI 10.1208/s12248-011-9316-3

Bibliografisk träff 2011-05-04

Macitentan: entry-into-humans study with a new endothelin receptor antagonist.

Sidharta PN, van Giersbergen PL, Halabi A, Dingemanse J.

Eur J Clin Pharmacol · research support, non-u.s. gov't; research-article; randomized controlled trial; journal article · DOI 10.1007/s00228-011-1043-2

Bibliografisk träff 2009-09-16

Comparison of the dissolution and pharmacokinetic profiles of two galenical formulations of the endothelin receptor antagonist macitentan.

Kummer O, Haschke M, Hammann F, Bodmer M, Bruderer S, Regnault Y, Dingemanse J, Krähenbühl S.

Eur J Pharm Sci · comparative study; research support, non-u.s. gov't; journal article · DOI 10.1016/j.ejps.2009.09.005

Bibliografisk träff 2008-09-09

Pharmacology of macitentan, an orally active tissue-targeting dual endothelin receptor antagonist.

Iglarz M, Binkert C, Morrison K, Fischli W, Gatfield J, Treiber A, Weller T, Bolli MH, Boss C, Buchmann S, Capeleto B, Hess P, Qiu C, Clozel M.

J Pharmacol Exp Ther · research support, non-u.s. gov't; journal article · DOI 10.1124/jpet.108.142976